English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

● Ulcerative interstitial cystitis (IC) is an inflammatory bladder condition with characteristic lesions (Hunner’s lesions) noted on cystoscopy that are associated with bladder pain and voiding frequency ● LiRIS®, a lidocaine-releasing intravesical system, is a passive, nonresorbable, intravesical system designed to provide continuous, controlled release of lidocaine into the bladder over a 2-week period ● A previous study in IC patients demonstrated beneficial changes in lesion reduction with LiRIS.1 This study attempted to replicate those findings in a pure Hunner’s lesion population

MP72-16 SAFETY, TOLERABILITY, AND PRELIMINARY EFFICACY OF LIRIS® 400 MG IN WOMEN WITH ULCERATIVE INTERSTITIAL CYSTITIS